RELMADA THERAPEUTICS, INC. Payments of Stock Issuance Costs
RELMADA THERAPEUTICS, INC. (RLMD) reported Payments of Stock Issuance Costs of $131.92 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-08-06
- RELMADA THERAPEUTICS, INC. payments of stock issuance costs for the quarter ending 2026-06-30 was $66.27K.
- RELMADA THERAPEUTICS, INC. payments of stock issuance costs for the quarter ending 2026-03-31 was $65.65K.
- RELMADA THERAPEUTICS, INC. payments of stock issuance costs for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- RELMADA THERAPEUTICS, INC. payments of stock issuance costs for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- RELMADA THERAPEUTICS, INC. payments of stock issuance costs for fiscal 2025 was $73.02K, a 74.56% decline from fiscal 2024.
- RELMADA THERAPEUTICS, INC. payments of stock issuance costs for fiscal 2024 was $287.09K, a 191.57% increase from fiscal 2023.
- RELMADA THERAPEUTICS, INC. payments of stock issuance costs for fiscal 2023 was $98.46K.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $66.27K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $131.92K 10-Q · filed 2026-08-06 | $131.92K derived: sum of 3 quarters · filed 2026-08-06 | $131.92K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $65.65K 10-Q · filed 2026-05-12 | $65.65K derived: sum of 2 quarters · filed 2026-05-12 | $65.65K derived: sum of 3 quarters · filed 2026-05-12 | |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $0.00 derived: sum of 2 quarters · filed 2026-03-19 | $73.02K 10-K · filed 2026-03-19 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $73.02K 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | $73.02K 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $172.49K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $262.09K derived: sum of 2 quarters · filed 2026-03-19 | $262.09K derived: sum of 3 quarters · filed 2026-03-19 | $287.09K 10-K · filed 2026-03-19 |
| 2024-09-30 | $89.60K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $89.60K derived: sum of 2 quarters · filed 2025-11-13 | $114.60K 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $25.00K 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $25.00K 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $98.46K 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |